anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PCT No. PCT/CH89/00002 Sec. 371 Date Sep. 6, 1989 Sec. 102(e) Date Sep. 6, 1989 PCT Filed Jan. 6, 1989 PCT Pub. No. WO89/06156 PCT Pub. Date Jul. 13, 1989.A molecular sieve material is combined with a porous carrier material. The pores of the molecular sieve material are impermeable to molecules or organisms having a size equal to or greater than that of the water molecule either because the molecular sieve material is selected so as to have pores which are smaller than such molecule or because the pores of the molecular sieve material are closed by a film. The pores of the molecular sieve material thus remain unoccupied and are able to exert an attractive force on molecules or organisms which are to be captured. The pores of the carrier material are designed to accept molecules or organisms having a size equal to or greater than that of the water molecule so that, when such molecules or organisms are attracted by the molecular sieve material, they can be trapped in the carrier material.
Pain is a widespread motivation for seeking healthcare and stands as a substantial global public health concern. Despite comprehensive investigations into the mechanisms of pain sensitization induced by inflammation, efficacious treatments options remain scarce. Neutrophil extracellular traps (NETs) have been associated with the progression and tissue damage of diverse inflammatory diseases. This study aims to explore the impact of NETs on the progression of inflammatory pain and explore potential therapeutic approaches. Initially, we observed neutrophil infiltration and the formation of NETs in the left hind paw of mice with inflammatory pain induced by complete Freund's adjuvant (CFA). Furthermore, we employed the peptidyl arginine deiminase 4 (PAD4) inhibitor Cl-amidine (diluted at 50 mg/kg in saline, administered via tail vein injection once daily for three days) to impede NETs formation and administered DNase1 (diluted at 10 mg/kg in saline, once daily for three days) to break down NETs. We investigated the pathological importance of peripheral NETs formation in inflammatory pain and its influence on the activation of spinal dorsal horn microglia. The findings indicate that neutrophils infiltrating locally generate NETs, leading to an increased release of inflammatory mediators that worsen peripheral inflammatory reactions. Consequently, this results in the transmission of more harmful peripheral stimuli to the spinal cord, triggering microglial activation and NF-κB phosphorylation, thereby escalating neuroinflammation and fostering pain sensitization. Suppression of peripheral NETs can mitigate peripheral inflammation in mice with inflammatory pain, reverse mechanical and thermal hypersensitivity by suppressing microglial activation in the spinal cord, ultimately diminishing inflammatory pain. In conclusion, these discoveries propose that obstructing or intervening with NETs introduces a novel therapeutic avenue for addressing inflammatory pain.
BACKGROUND: Cerebral venous sinus thrombosis (CVST) is a rare cause of stroke. Acquired and inherited prothrombotic conditions are the most common risk factors for CVST. Sometimes, an etiology is not found. Wide utilization of next generation sequencing technologies in clinical practice may lead to identification of risk factors other than those classically associated with CVST.
METHOD AND RESULTS: This retrospective clinical-laboratory observational study has a reference patient who presented with CVST as an adolescent. Work up for prothrombotic conditions showed high homocysteine level secondary to homozygosity for a common polymorphism, c.677 C > T in the methylenetetrahydrofolate reductase (MTHFR) gene. His older unaffected brother has a similar MTHFR genotype and high homocysteine. The whole exome sequencing revealed a likely pathogenic variant in the sodium voltage gated channel, alpha subunit 1(SCN1A) gene.
CONCLUSION: CVST is a multifactorial disease. Prothrombotic conditions are the most common risk factors for CVST. High homocysteine due to the common MTHFR polymorphisms was previously attributed to various thrombotic conditions including CVST. Although high homocysteine due to MTHFR polymorphism may be a contributing factor, additional risk factors such as blood flow abnormalities during SCN1A related seizures may be needed for thrombosis.
OBJECTIVE: The purpose of the study was to determine if antegrade continence enema (ACE) alone is an effective treatment for patients with severe functional constipation and segmental colonic dysmotility.
METHODS: A retrospective study of patients with functional constipation and segmental colonic dysmotility who underwent ACE as their initial means of management. Data was collected from six participating sites in the Pediatric Colorectal and Pelvic Learning Consortium. Patients who had a colonic resection at the same time as an ACE or previously were excluded from analysis. Only patients who were 21 years old or younger and had at least 1-year follow-up after ACE were included. All patients had segmental colonic dysmotility documented by colonic manometry. Patient characteristics including preoperative colonic and anorectal manometry were summarized, and associations with colonic resection following ACE were evaluated using Fisher's exact test and Wilcoxon rank-sum test. p-Values of less than 0.05 were considered significant. Statistical analyses and summaries were performed using SAS version 9.4 (SAS Institute Inc., Cary, North Carolina, United States).
RESULTS: A total of 104 patients from 6 institutions were included in the study with an even gender distribution (males n = 50, 48.1%) and a median age of 9.6 years (interquartile range 7.4, 12.8). At 1-year follow-up, 96 patients (92%) were successfully managed with ACE alone and 8 patients (7%) underwent subsequent colonic resection for persistent symptoms. Behavioral disorder, type of bowel management, and the need for botulinum toxin administered to the anal sphincters was not associated with the need for subsequent colonic resection. On anorectal manometry, lack of pelvic floor dyssynergia was significantly associated with the need for subsequent colonic resection; 3/8, 37.5% without pelvic dyssynergia versus 1/8, 12.5% (p = 0.023) with pelvic dyssynergia underwent subsequent colonic resection.
CONCLUSION: In patients with severe functional constipation and documented segmental colonic dysmotility, ACE alone is an effective treatment modality at 1-year follow-up. Patients without pelvic floor dyssynergia on anorectal manometry are more likely to receive colonic resection after ACE. The vast majority of such patients can avoid a colonic resection.
A computer-implemented method, computer program product and computer system (100) for predicting the risk of a patient (10) to develop an atherosclerotic cardiovascular disease within a predefined time interval. The system receives a current set of risk factors associated with the risk of atherosclerotic plaque build-up in the patient's arteries. The current set comprises a set of human-curated risk factors covering multiple biological levels of the patient to capture the potential interactions or correlations detected between molecules in different biological levels. A predictor (110) receives the current set as test input to, wherein the predictor has been trained with a training data set (300) including a number of training patient records. The training data set includes risk factor training values (310 to 350) corresponding to the same set of variables as included in the test input of said patient, (10) and serving as training inputs. The training data set further includes atherosclerotic cardiovascular disease outcomes (390) of the training patients (90) serving as ground truth. The risk factor training values and the outcomes were obtained over a training data collection period of at least the length of the predefined time interval. None of the training patients (90) has shown an atherosclerotic cardiovascular disease outcome up to the beginning of the training data collection period. The predictor (110) provides, in response to the test input, a predicted risk (111) for developing an atherosclerotic cardiovascular disease for said patient (10) within the predefined time interval.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

VESIcare has been evaluated for safety in 1811 patients in randomized, placebo-controlled trials. Expected adverse reactions of antimuscarinic agents are dry mouth, constipation, blurred vision (accommodation abnormalities), urinary retention, and dry eyes. The incidence of dry mouth and constipation in patients treated with VESIcare was higher in the 10 mg compared to the 5 mg dose group. 

In the four 12-week double-blind clinical trials, severe fecal impaction, colonic obstruction, and intestinal obstruction were reported in one patient each, all in the VESIcare 10 mg group. Angioneurotic edema has been reported in one patient taking VESIcare 5 mg. Compared to 12 weeks of treatment with VESIcare, the incidence and severity of adverse reactions were similar in patients who remained on drug for up to 12 months. 

The most frequent adverse reaction leading to study discontinuation was dry mouth (1.5%). Table 1 lists the rates of identified adverse reactions, derived from all reported adverse events, in randomized, placebo-controlled trials at an incidence greater than placebo and in 1% or more of patients treated with VESIcare 5 or 10 mg once daily for up to 12 weeks.
Investigators will study the efficacy of DCS for augmenting therapeutic learning relevant for the treatment of depression (i.e., outside the extinction learning where DCS has been shown to have success). Specifically, the study investigates the role of DCS in enhancing declarative memory in depressed individuals, as evaluated by standardized tests and the retention of cognitive therapy session material. Investigators will also study an active comparison agent, modafinil, which appears to offer cognitive enhancing effects among both sleep-deprived and non-sleep-deprived individuals, but also appears to have drug-state (e.g., mood and side) effects that are not characteristic of DCS augmentation. Therefore, drug-context effects may affect memory retention over time. Hence, the study will evaluate memory enhancement effects both during the period of drug action as well as one week later when no drug is taken. Overall, investigators will examine cognitive function and memory performance over 4 study sessions in 96 men and women with major depression, who, in a double-blind fashion, will be randomly assigned to either: (1) 250mg DCS, (2) 100mg modafinil, or (3) placebo administered on Study Weeks 2 and 3. The memory tests include both items unique to a given study week and memory tasks that are repeated over time that allow assessment of memory and retention effects across one-week periods.
<P>PROBLEM TO BE SOLVED: To provide a locally applying preparation improving the wetting property of contact lenses and increasing the amount of tear liquid.  <P>SOLUTION: This ocular locally applying preparation containing (a) alginic acid or its salt and (b) menthol and/or camphor. Further, the ocular locally applying preparation contains 1 kind or ≥2 kinds of compounds selected from borneol. geraniol, cineol, linalyl acetate or menthone, and a nonionic surfactant such as a polyoxyethylene-polyoxypropylene block copolymer, etc. By the preparation, the wetting property of the contact lenses is improved, the amount of the tear liquid is increased, and an effect of moistening eyes is exhibited.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The present invention provides a method of isolating mucilaginous polysaccharides from plants, cereals, cell cultures, or fungi such as mushrooms known to have mucilaginous or protein-bound polysaccharides with desirable biological properties. The mucilaginous polysaccharides present in aqueous solution or tissue extracts are treated with tannins to form a complex which is then separated from the solution. The complex is then treated one or more times with either solvents or other substances in solution to remove the bounded tannins from the complex thereby and releasing the isolated polysaccharide. The polysaccharides prepared according to the present method retain properties that are substantially similar to those of the native polysaccharide as it is found in the respective plant or cell. The polysaccharides thus prepared are used in a variety of products. This process is particularly suitable for isolating acetylated mannose polymers from aloe plants and beta glucans.
Several such biologic meshes have now been developed and marketed for use in hernia repair and soft tissue reconstruction. These biologics include one product derived from porcine intestinal submucosa (SurgisisTM, Cook Medical), another derived from porcine dermis (CollaMendTM, C.R. Bard Inc.) and several others derived from decellularized human dermis, such as AlloDermTM (LifeCell Corp.), AlloMaxTM (C.R. Bard Inc.), and FlexHDTM (Musculoskeletal Transplant Foundation). Although similar in concept and design, each of these biologic meshes is produced in a distinct, proprietary fashion, and different techniques are used by each company in the processing and storage of their respective products. Given that these processing steps are protected industrial intellectual property, rigorous comparison of the performance of each mesh is very difficult. It is expected that certain methods, such as employing or avoiding chemical cross-linking of the ECM proteins, would lead to significant differences in cell migration into, and biochemical remodeling of each individual mesh. These differences may be of particular importance in the scenario of laparoscopic ventral hernia repair, where the mesh is placed in direct apposition to the parietal peritoneum. In this case, if the biologic were to remodel and take on more of the properties of the distensible peritoneum rather than that of the stronger abdominal wall fascia, this could have a significant impact on the long-term strength and durability of the hernia repair. A similar situation could also be foreseen to occur at the esophageal hiatus and/or the site of an intestinal stoma. We feel that it is thus important to study the remodeling processes that these meshes undergo over time and determine if differences in product processing or anatomical position have any effect on mesh incorporation and hernia integrity. Many of these meshes have already been used in human subjects, yet a certain number of these patients are known have suffered hernia recurrences requiring reoperation and removal of some or all of the original mesh prostheses. It is our belief that these biologic explants represent an excellent source of material to study the remodeling process over numerous given time points and at various anatomic locations. We feel it is also important to compare the explanted biologic meshes to "control" tissues, to examine how successfully the biologic meshes are mimicking native tissue at the molecular and histologic level. To eliminate confounding factors, explanted meshes will be compared to biopsies of abdominal wall fascia from patients undergoing non-hernia related surgical procedures.
The use of optionally (cyclo)alkyl etherified or cinnamic acid esterified cycloartenol compounds (I) in cosmetic, dietetic or pharmaceutical compositions for treating wrinkles and improving or treating cutaneous relief is new. The use of cycloartenol compounds of formula (I) is claimed in the production of cosmetic, dietetic or pharmaceutical compositions for treating wrinkles and improving or treating cutaneous relief. [Image] R : H, 2-30C alkyl, 3-30C cycloalkyl or a cinnamic acid (or derivative) ester residue. An independent claim is included for cosmetic, dietetic or pharmaceutical compositions for use as above, containing (I) together with another cosmetic active agent (II) comprising genistein or diosgenin. ACTIVITY : Dermatological; Antiinflammatory. MECHANISM OF ACTION : Mitochondrial metabolism activator; Antiradical.
The invention relates to a broad-spectrum antiviral nano traditional Chinese medicine and a preparation method thereof. The broad-spectrum antiviral nano traditional Chinese medicine is prepared by using 36 traditional Chinese medicines as the effective raw materials by weight: 30 to 60 of prepared common monkshood daughter root, 10 to 20 of ephedra herb, 15 to 30 of cassia twig, 30 to 60 of medicinal indianmulberry root and the like. The preparation method comprises the following steps of pretreatment grinding, high-frequency ultrasonic grinding, extraction and dispersion, microwave extraction, ultrasonic spraying, drying and grinding, nano grinding, mixing, Capsule filling and sterilizing. The formula has broad-spectrum antiviral and anti-tumor treatment effects, has no any toxic or side effect, and is suitable for treating various virus carriers. By syndrome differentiation and treatment, pharmacodynamics analysis, medicament channel tropism, yin and yang distinguishing, body resistance strengthening and pathogenic factor elimination and monarch, subject, assistant and envoy reasonable compatibility, the formula is subdivided into four morning, noon, evening and night preparation formulations which are suitable for the user to administrate at four times respectively. The traditional Chinese medicine is applied onto the local skins of the human body according to different times to carry out acupoint drug administration and percutaneous absorption treatment.
Participants will be included in 2 pre-intervention and 2 post-assessment measures. The additional pre-intervention assessment will allow for assessment of stability of measures. Participants will receive the Listening Project Protocol intervention (filtered music). The duration of the intervention is approximately 60 minutes per day, for 5 consecutive days.
Postoperative sore throat (POST) is a minor complication after general anesthesia with tracheal intubation but may negatively affect patient satisfaction and postoperative recovery. Due to the multifactorial nature, the detailed mechanism of POST has not been fully understood. However, mucosal irritation and inflammation related to the presence of an ETT within the trachea appear to be one of the primary causes of POST, which may involve elements including the tube size, intracuff pressure, and duration of intubation. In addition, the cuff design of an ETT, which can determine the contact area between the cuff and the tracheal mucosa, is reported to affect the development of POST. This study aimed to evaluate the impact of endotracheal tube (ETT) cuff shapes on the incidence and severity of POST. Additionally, we investigated the influence of ETT cuff shapes on the degree of subglottic injury following GA for breast cancer surgery.
Prepare for the possibility of drug hypersensitivity reactions (including anaphylaxis), which can occur during or following administration, and take the necessary precautions. 

In clinical studies, 4 of 726 (0.6%) patients treated with LUMISIGHT experienced signs and symptoms consistent with anaphylaxis. The onset was during administration in three patients. Signs and symptoms associated with other hypersensitivity reactions included pruritus, urticaria, hypotension, lip swelling, erythema, anxiety, chest pain, cyanosis, dizziness, dyspnea, headache, hypoesthesia, hyperventilation, maculopapular rash, nausea, paresthesia, visual changes, and vomiting [see Adverse Reactions (6.1)].

Before LUMISIGHT administration, assess all patients for any history of hypersensitivity reaction to contrast media or products containing polyethylene glycol (PEG), as these patients may have an increased risk for hypersensitivity reaction to LUMISIGHT. In clinical studies, three out of four patients that experienced anaphylaxis did not have a history of hypersensitivity reaction to contrast media or products containing PEG.

Always have emergency resuscitation drugs, equipment, and trained personnel available. Monitor all patients for hypersensitivity reactions through symptom reporting, direct observation, and vital sign measurements. If a hypersensitivity reaction is suspected, immediately discontinue the injection and initiate appropriate therapy. LUMISIGHT is contraindicated in patients with a history of hypersensitivity reaction to pegulicianine [see Contraindications (4)].
PROBLEM TO BE SOLVED: To directly prepare a mycelium extract without extraction by cultivating mycelium of Agaricus blazei Murill under a specific condition, and propagating the mycelium while perishing various germs by an aeration. SOLUTION: Mycelium of Agraicus blazei Murill in a concentration of 30-150 g/L cultivation liquid is cultured in a medium at a temp. of 0-25 deg.C for >=1 week. The cultured liquid temperature is raised to >=30 deg.C during 1-4 days under 1-10 atm to separate the mycelium of the Agaricus blazei Murill. The liquid temperature is raised to >=50 deg.C at once while ventilating air and kept for 1-4 hr, and the liquid is stool to cool to a normal temperature and filtered after 1-15 hr. The obtained liquid is allowed to stand at a temp. of 15-30 deg.C for 1-4 hr to propagate various germs, allowed to stand at the normal temperature for 1-5 days while aerating to propagate the mycelium, kept for 12-36 hr after stopping the aeration and filtered while aerating.  The filtered liquid is allowed to stand at the normal temperature for 2-7 hr while aerating, and thereafter the liquid is kept at a temp. of >=60 deg.C for 30 min to 4 hr to perish the various germs. The obtained liquid is further subjected to other treatments to provide the objective extract in the method for preparing the objective extract.
Disclosed herein is an oral pharmaceutical composition in the form of an aqueous solution of atomoxetine as an active ingredient. The aqueous solution of atomoxetine comprises a taste-masked liquid carrier comprising peppermint, orange flavor and a viscosity agent. The combined flavors successfully masked atomoxetine hydrochloride's bitter smell and/or taste which makes it a novel palatable pharmaceutical composition. The viscosity agent improves the oral pharmaceutical composition's consistency and provides a smooth texture which makes it easy to swallow. More specifically, the oral pharmaceutical composition comprises effective amounts of: (a) atomoxetine or the pharmaceutically acceptable salts thereof; and (b) a taste-masked liquid carrier. Also provided is a method for making the aqueous solution of atomoxetine. The present disclosure also provides methods of using oral pharmaceutical composition for the treatment of a subject having a disorder treatable by the administration of atomoxetine. In one embodiment, the disorder is attention deficit hyperactivity disorder (ADHD).
Prospective observational multicenter case series providing short-term migration results and long-term post-market clinical data on the safety and performance of the aneXys cup. The study includes patients undergoing primary total hip arthroplasty. In total 100 patients in 3 clinics will be included. In each clinic 10-57 consecutive patients shall be included. In addition, to meet the regulatory requirements, a total of minimum 20 cases with screw fixation shall be included in the study.

Clinical and radiological follow-up (FU) is planned after 6-12 weeks, 6 months, 1, 2, 5, 7 and 10 years. An additional FU at 3 years is planned to apply for an ODEP (Orthopaedic Data Evaluation Panel) rating.